Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today
Palantir Technologies Inc (NYSE: PLTR) shares are trading higher by 4.0% to $15.74 during Friday's session, rebounding following Thursday weakness. The stock is rebounding Friday following better-than-expected U.S.
Safe Bulkers, Inc. (the "Company" or "Safe Bulkers") (NYSE:SB), an international provider of marine drybulk transportation services, announced today that it has authorized a program under which it may from time to time